ANGPTL4 and metabolic syndrome: Moreover, PCSK5 might be a potential target to lower LDL levels (De Vries et al. 2019) and valuable for the ANGPTL4 (angiopoietin like 4)-mediated target therapy of diabetes and metabolic syndrome (Li and Teng 2014).